ClinicalTrials.gg
RecruitingNCT05999110A3-CORUpdated Feb 8, 2024

Algarve Active Ageing - Cardiac and Osteoarthritis Rehabilitation (A3-COR)

An interventional study of Physical Exercise in Osteoarthritis, Knee, Myocardial Infarction, Acute and Hypertension, sponsored by Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv. Recruiting at 1 site in Portugal. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-02-08.

Sponsored by Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 2 months after the study started (first participant enrolled Jun 2022, registered Aug 2023).
  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis, Knee with a site in Portugal — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Portugal.

Planned enrollment
5th of 11
200 · median 88
Started
2022
with 1 other
No phase
7 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv

Among the 12 studies in Osteoarthritis, Knee with a site in Portugal, this one is the 5th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 7 with no phase, and was the 9th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 12 studies in Osteoarthritis, Knee with a site in Portugal are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis, Knee with a site in Portugal, or all of them as a file.
02

Study summary

This study aims to develop, implement, and determines the effectiveness of a personalized medicine approach to each individual's phenotype, based on an innovative physical exercise program to promote the treatment of pain and functional limitation resulting from knee osteoarthritis (KOA) in patients recovering after acute myocardial infarction (AMI) and cardiovascular risk (CVR).

This randomized clinical study is important due to the lack of evidence according to the effectiveness of a personalized physical exercise intervention in people after MI or CVR with simultaneous KOA.

Some studies have shown the existence of a relationship between OA and cardiovascular diseases (CVD), including coronary artery disease, stroke, congestive heart failure, peripheral arterial disease, cardiac procedures, or death related to CVD, since individuals with OA have a higher prevalence of CVD than individuals without OA.

Sedentary behaviour is a risk factor for AMI, CVR and KOA, and, at the same time, physical exercise is a common non-pharmacological treatment for people suffering from these conditions, namely in the control of joint pain, gains in functional capacity, and the improvement of cardiorespiratory functional capacity, whose impact can be felt in level of quality of life.

Chronic diseases have a significant impact on the global burden of disease, particularly CVD and OA, with the added presence of obesity also contributing to a high rate of all-cause morbidity and mortality, representing a substantial health burden and with growing implications for individuals, health systems and socioeconomic costs.

The presence of OA seems to lead to an increased risk of developing CVD. Several mechanisms have been proposed to explain this relationship. Chronic inflammation associated with OA is one of the hypotheses suggested to explain the increased risk of CVD in these individuals. Furthermore, the pain and disability associated with OA may also limit participation in exercise/physical activity, influencing other risk factors associated with both chronic diseases, such as weight gain.

The lack of studies about physical exercise intervention on people that suffered acute myocardial infarction or is in cardiovascular risk with simultaneous knee osteoarthritis and the lack of offer of phase III cardiac rehabilitation in Algarve motivated the development of this study, with the assumption of adopting a healthier lifestyle.

Read the detailed description

A new exercise protocol (A3-COR Protocol) for patients with knee osteoarthritis (OA) recovering after acute myocardial infarction (AMI) or with cardiovascular risk (CVR) was developed and implemented. The purpose of the A3-COR protocol is to improve quality of life, functionality, and pain, through regular physical exercise facilitating an active and healthy lifestyle.

This clinical trial includes 2 parallel intervention groups with a pre- and post-test analysis. In the exercise group (EG), the participants will receive a twelve weeks of a supervised personalised exercise program and in the control group (CG) there will be no intervention. Both groups will have a behavioral change session with a psychologist to promote changes in lifestyle and a session with a nutritionist to promote healthy eating habits.

Both groups will be assessed two times, the pre-test in the beginning of the study (T0-Baseline) before starting the intervention or control and the post-test taking place at the end of 12 weeks (T1-Post-test).

The sample includes subjects from the community who met the defined eligibility criteria. Participation in the study is voluntary and sample recruitment will be carried out through publicity materials, such as flyers posted at senior universities, institutions/associations, municipalities, parish councils, sports complexes, health centres, among other public spaces of interest.

To calculate the sample size, the software G*Power was used. The primary outcome for this clinical trial was the knee-related pain, measured by the Knee Injury and Osteoarthritis Outcome Score (KOOS) with is a self-reported outcome with five subscales: 1) Symptoms+Stiffness; 2) Pain; 3) Function, daily living; 4) Function, sports and recreational activities and 5) Quality of Life, all score 0-100. According to the literature, an important clinical difference in the KOOS subscales has been suggested to be 8 to 10 points. Based on the expected difference of 10 points between the intervention and control groups and a standard deviation of 20 in Pain, 64 patients were required in each group with a significance level of 0.05 and power of 80%. With an estimated dropout rate of 10%, a total number of 142 subjects will be randomized to the EG (n = 71) and to the CG (n = 71).

The screening for acute myocardial infarction will be done with the presence of myocardial lesion detected by abnormal cardiac biomarkers evidencing acute myocardial ischemia. The screening of cardiovascular risk will consider the presence of any of the following cardiovascular risk factors: hypertension, dyslipidemia, or smoking habits, according to the SCORE2 or SCORE2 O.P. The screening of knee osteoarthritis will be done according to the National Institute for Health and Excellence (NICE) (2022)(NG226), EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis (2009) and American College of Rheumatology (ACR)(1986) clinical criteria. To identify participants with cognitive impairment, the Montreal Cognitive Assessment (MoCA) instrument was applied and cutoff points for the Portuguese population considering age and educational level were used.

The training sessions combine cardiorespiratory exercises for the development of aerobic capacity and strength exercises, particularly resistant strength, in tasks that include open and closed chain exercises, using your own body weight and equipment for this purpose. The training zones are defined according to the performance of each individual in the test of cardiorespiratory fitness in effort and test of maximum isokinetic strength, carried out in the baseline.

03

Conditions studied

  • Osteoarthritis, Knee
  • Myocardial Infarction, Acute
  • Hypertension
  • Dyslipidemias
  • Type 2 Diabetes
  • Smoking Habit

Keywords

  • Knee Osteoarthritis
  • Acute Myocardial Infarction
  • Cardiovascular Risk
  • Personalized Medicine
  • Healthy Ageing
  • Exercise
  • Personalized Exercise
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 50 or older; Knee pain, Morning stiffness that lasts no longer than 30 minutes and one of the following: crepitus, restricted function, bony enlargement. Acute Myocardial Infarction with myocardial lesion detected by abnormal cardiac biomarkers evidencing acute myocardial ischemia; High risk level in the Systematic Coronary Risk Evaluation (SCORE2) or the Systematic Coronary Risk Evaluation Older Person (SCORE2 O.P.) cardiovascular risk algorithm or prior cardiovascular disease; Independent gait

Exclusion criteria

Exclusion Criteria:

  • Occurrence of acute myocardial infarction with less than 12 months; Cognitive impairment- (MoCA); Type 1 diabetes or insulin dependence; Pacemaker device; Knee prosthesis; Currently doing formal exercise session for more that 30 minutes per week; Class III or IV angina according to Canadian Cardiovascular Society criteria; Class III or IV symptoms according to criteria; Type 2 Myocardial Infarction; Uncontrolled and symptomatic cardiac arrythmia with hemodynamic impact; Severe and symptomatic aortic valve stenosis; Uncontrolled and symptomatic heart failure; Active myocarditis, pericarditis or endocarditis; Acute aortic syndrome; Known or suspected desiccant aneurism; Acute systemic infection.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Exercise Group

    The participants receive twelve weeks of a supervised personalised exercise program, based on aerobic and strength training. This group also receives a behavioral change session with a psychologist and nutritional advice session with a nutritionist.

    Other: Physical Exercise

  • No intervention
    Control Group

    This group receive no exercise intervention. The group receives equally as the exercise group, a behavioral change session with a psychologist and nutritional advice session with a nutritionist.

Interventions

  • OtherPhysical Exercise

    The intervention includes a personalized physical exercise program based on aerobic and strength training, with prior warm-up and post cool-down exercises. All participants also receive a nutritional advice session and a behavioral changes session.

06

What researchers measure

Primary outcomes

  1. Change the Level of Pain

    Significant increase in pain subscore of Knee Injury and Osteoarthritis Outcome Score. The subscore can range between 0-100% and higher values mean less pain.

    Time frame: 12 weeks

  2. Change the Level of Function

    Significant increase in both function subscores of Knee Injury and Osteoarthritis Outcome Score. The subscores can range between 0-100% and higher values mean better function.

    Time frame: 12 weeks

  3. Change the Time Up and Go Test Performance

    Significant decrease in time (seconds) to perform the Timed Up and Go (TUG) test. Higher time of performance means poorer physical function.

    Time frame: 12 weeks

  4. Change the 30-Second Chair Stand Test Performance

    Significant increase of number of repetitions in 30-second chair stand test. Higher number of repetitions in 30 seconds means better physical function.

    Time frame: 12 weeks

  5. Change the 40m Fast Paced Walk Test Performance

    Significant decrease in time (seconds) of performance in 40m fast paced walk test. Higher time of performance means poorer physical function.

    Time frame: 12 weeks

  6. Change the Stair Climb Test Performance

    Significant decrease in time (seconds) of performance in Stair Climb Test (9 steps). Higher time of performance means poorer physical function.

    Time frame: 12 weeks

  7. Change the 6 Minutes Walk Test Performance

    Significant increase in distance (meters) in 6 Minutes Walk Test. Higher distance in 6 minutes means better physical function.

    Time frame: 12 weeks

  8. Change in Quality of Life

    Significant increase in any subscore or total score of Medical Outcomes Study 36-item Short-Form Health Survey (SF-36), used to assess quality of life. Instrument can range between 0-100 and higher values mean better self-precepted quality of life.

    Time frame: 12 weeks

  9. Change in Peak Torque of Quadriceps and Hamstring Muscles

    Significant increase in peak torque (N/m). Peak Torque of Quadriceps and Hamstring Muscles will be measured by a fixed dynamometer with concentric/concentric action at an angular velocity of 60º per second for 5 repetitions of extension and flexion of each knee.

    Time frame: 12 weeks

  10. Change in Work of Quadriceps and Hamstring Muscles

    Significant increase in work per repetition (N/m). Work of Quadriceps and Hamstring Muscles will be measured by a fixed dynamometer with concentric/concentric action at an angular velocity of 60º per second for 5 repetitions of extension and flexion of each knee.

    Time frame: 12 weeks

  11. Change in Power of Quadriceps and Hamstring Muscles

    Significant increase in power per repetition (N/m). Power of Quadriceps and Hamstring Muscles will be measured by a fixed dynamometer with concentric/concentric action at an angular velocity of 60º per second for 5 repetitions of extension and flexion of each knee.

    Time frame: 12 weeks

  12. Change in Peak torque time of Quadriceps and Hamstring Muscles

    Significant increase in Peak torque time (s). Peak torque time of Quadriceps and Hamstring Muscles will be measured by a fixed dynamometer with concentric/concentric action at an angular velocity of 60º per second for 5 repetitions of extension and flexion of each knee.

    Time frame: 12 weeks

  13. Change in Force of Quadriceps and Hamstring Muscles

    Significant increase in Force (kg). Force of Quadriceps and Hamstring Muscles will be measured by a fixed dynamometer with concentric/concentric action at an angular velocity of 60º per second for 5 repetitions of extension and flexion of each knee.

    Time frame: 12 weeks

  14. Change in Maximal Oxygen Uptake (VO2max)

    Significant increase in Maximal Oxygen Uptake (VO2max). Higher VO2max means better cardiorespiratory function. The VO2max will be evaluated through the exercise cardiorespiratory test with progressive increase of the external load by the manipulation of the velocity or inclination.

    Time frame: 12 weeks

  15. Change in First Ventilatory Threshold (VT1 - VO2)

    Significant increase in First Ventilatory Threshold (VT1 - VO2). Higher VT1 means better cardiorespiratory function. The VT1 will be evaluated through the exercise cardiorespiratory test with progressive increase of the external load by the manipulation of the velocity or inclination.

    Time frame: 12 weeks

  16. Change in Respiratory Compensation Point (RCP - VO2)

    Significant increase in Respiratory Compensation Point (RCP - VO2). Higher RCP means better cardiorespiratory function. The RCP will be evaluated through the exercise cardiorespiratory test with progressive increase of the external load by the manipulation of the velocity or inclination.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in maximal displacement of vastus lateralis and medialis, biceps femoris and semitendinous

    Significant change maximal displacement (mm) of vastus lateralis and medialis, biceps femoris and semitendinous. Higher radial muscle belly displacement means poor muscle function and muscle atrophy. The muscle displacement will be measured by a tensiomyography system (TMG S2).

    Time frame: 12 weeks

  2. Change in contraction time of vastus lateralis and medialis, biceps femoris and semitendinous

    Significant change in contraction time of vastus lateralis and medialis, biceps femoris and semitendinous. The contraction time will be measured by a tensiomyography system (TMG S2).

    Time frame: 12 weeks

  3. Change in Weight

    Significant decrease in weight (kg). Higher values of weight mean poor body composition and health. The weight will be measured using bioimpedance.

    Time frame: 12 weeks

  4. Change in body mass index

    Significant decrease in body mass index (kg/m2). Higher values of body mass index mean poor body composition and health. The body mass index will be measured using bioimpedance.

    Time frame: 12 weeks

  5. Change in fat mass

    Significant decrease in fat mass (kg and %)). Higher values of fat mass mean poor body composition and health. The fat mass will be measured using the bioimpedance.

    Time frame: 12 weeks

  6. Change in fat-free mass

    Significant increase in fat-free mass (kg and %). Higher values of fat-free mass mean better body composition and health. The fat-free mass will be measured using the bioimpedance.

    Time frame: 12 weeks

  7. Change in fat mass index

    Significant decrease in fat mass index (kg/m2). Higher values of fat mass index mean poor body composition and health. The fat mass index will be measured using the bioimpedance.

    Time frame: 12 weeks

  8. Change in fat-free mass index

    Significant increase in fat-free mass index (kg/m2). Higher values of fat-free mass index mean better body composition and health. The fat-free mass index will be measured using the bioimpedance.

    Time frame: 12 weeks

  9. Change in muscle mass index

    Significant increase in muscle mass index (kg/m2). Higher values of muscle mass index mean better body composition and health. The muscle mass index will be measured using the bioimpedance.

    Time frame: 12 weeks

  10. Change in total body water

    Significant increase in total body water (L and %). Higher values of total body water mean better body composition and health. The total body water will be measured using the bioimpedance.

    Time frame: 12 weeks

  11. Monitoring phase angle

    Keep the phase angle within normal limits for the age. The phase angle will be measured using the bioimpedance.

    Time frame: 12 weeks

  12. Change in fat visceral fat

    Significant decrease in visceral fat (L). Higher values of visceral fat mean poor body composition and health. The visceral fat will be measured using the bioimpedance.

    Time frame: 12 weeks

  13. Change in abdominal circumference

    Significant decrease in abdominal circumference (cm). Higher values of abdominal circumference mean poor body composition and health. The abdominal circumference will be measured using measure tape, according to the STEPS Manual of the World Health Organization.

    Time frame: 12 weeks

  14. Change in Hand Grip Strength

    Significant increase in hand grip strength (kg). Higher hand grip strength is correlated with higher functional status. Maximum handgrip strength will be measured with the Lafayette Digital and Dynamometer manual digital dynamometer on the dominant upper limb.

    Time frame: 12 weeks

  15. Change in Rescue's Pain Medication Posology

    Decrease the necessity of rescue's pain medication related with knee osteoarthritis.

    Time frame: 12 weeks

  16. Change in hospital readmissions related to Myocardial Infarction

    Decrease hospital readmissions related with Myocardial Infarction.

    Time frame: 12 weeks

  17. Change medical appointments number related with Myocardial Infarction

    Reduce the number of appointments related with Myocardial Infarction.

    Time frame: 12 weeks

  18. Change medical appointments number related with Knee Osteoarthritis

    Reduce the number of appointments related with Knee Osteoarthritis.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • AD-ABC
    Faro, Algarve 8005-139, Portugal
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2024, 23 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 23 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Aug 21, 2023
StartActual
Jun 1, 2022
Primary completionEst.
May 31, 2024
CompletionEst.
Dec 20, 2024
Last update
Feb 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05999110
Lead sponsor
Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv
Collaborators
European Regional Development Fund, Loulé Municipal Council, Albufeira Municipal Council, Quarteira Parish Council
Responsible party
Sandra Rafael Pais (Researcher, Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv) — Principal investigator
First posted
Aug 21, 2023
Start date
Jun 1, 2022
Primary completion
May 31, 2024 (estimated)
Completion
Dec 20, 2024 (estimated)
Last update
Feb 8, 2024

Study contacts

Marta S Botelho, PhD
Contact
marta.botelho@abcmedicalg.pt
+351 916785430
Sandra R Pais, PhD
principal investigator · AD-ABC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion